Previous studies demonstrated that Skp2 was commonly overexpressed and associated with poor prognosis in a variety of human cancers, including gastrointestinal cancer [27-29], breast cancer [30,31], prostate cancer [32,33], lung cancer [34,35] and nasopharyngeal cancer [14,21]. This evidence concerns the gene SKP2 and prostate cancer.